Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse‐Risk TP53 ‐Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
American Journal of Hematology · 2025-12 · 100 (12) · 2220-2229
DOI: 10.1002/ajh.70069 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Hematology, online erschienen am 10.09.2025. Verfasst von Yuhua Ru und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Given the dismal prognosis for patients with TP53 ‐mutated acute myeloid leukemia (AML), the optimal donor for those undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) remains unclear. We retrospectively analyzed adult patients with TP53 ‐mutated AML who underwent first allo‐HCT in CR1 between 2010 and 2021. Outcomes were compared among using a haploidentical donor (Haplo), a matched sibling donor (MSD), and a 10/10 matched unrelated donor (MUD). The analysis comprised 451 patients, including 86 Haplo, 117 MSD, and 248 MUD. Patients in the three groups were transplanted during a similar period. Haplo, MSD, and MUD groups experienced similar incidences of Day 180 Grades II–IV aGVHD (30.9% vs. 23.6% vs. 28.3%), Grades III–IV aGVHD (13.6% vs. 10.1% vs. 9.1%), 2‐year cGVHD (28.9.% vs. 30.9% vs. 25.6%) and extensive cGVHD (10.9% vs. 16.1% vs. 13.3%). By multivariate analysis, the outcomes were similar in the three groups. The MSD group was associated with a similar 2‐year overall survival (OS: 33.9%; p = 0.799), leukemia‐free survival (LFS: 30.5%; p = 0.956), relapse incidence (RI: 54.2%; p = 0.497), non‐relapse mortality (NRM: 15.3%; p = 0.368), and GVHD‐free, relapse‐free survival (GRFS: 21.8%, p = 0.957) when compared with the Haplo group (2‐year OS: 46.7%, LFS: 37.4%, RI: 40.8%, NRM: 21.7%, GRFS: 25.7%). The MUD group also experienced a similar 2‐year OS (36.9%; p = 0.892), LFS (31%; p = 0.904), RI (50.8%; p = 0.521), NRM (18.2%; p = 0.368) and GRFS (21.9%; p = 0.383) when compared with the Haplo group. In conclusion, outcomes of patients with TP53 ‐mutated AML undergoing allo‐HCT from a haploidentical donor were comparable to those from an MSD or 10/10 MUD HCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
- Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- EBMT Paris Office, Hôpital Saint Antoine, Sorbonne University, Paris, France.
- Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
- Oslo University Hospital, Oslo, Norway.
- University Hospital Eppendorf, Hamburg, Germany.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Ru, Y., Chen, J., Ferhat, A. T., Labussière-Wallet, H., Gedde-Dahl, T., Kröger, N., Socié, G., Yakoub-Agha, I., Eder, M., Mielke, S., Wu, D., Mohty, M., Ciceri, F., & Gorin, N. C. (2025). Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse‐Risk TP53 ‐Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 100(12), 2220-2229. https://doi.org/10.1002/ajh.70069
Vancouver
Ru Y, Chen J, Ferhat AT, Labussière-Wallet H, Gedde-Dahl T, Kröger N, et al. Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse‐Risk TP53 ‐Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 2025;100(12):2220-2229. doi:10.1002/ajh.70069
BibTeX
@article{Ru2025,
author = {Ru, Yuhua and Chen, Jia and Ferhat, Allain-Thibeault and Labussière-Wallet, Hélène and Gedde-Dahl, Tobias and Kröger, Nicolaus and Socié, Gérard and Yakoub-Agha, Ibrahim and Eder, Matthias and Mielke, Stephan and Wu, Depei and Mohty, Mohamad and Ciceri, Fabio and Gorin, Norbert-Claude},
title = {Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse‐Risk TP53 ‐Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {12},
pages = {2220--2229},
doi = {10.1002/ajh.70069}
}
EUVIMED